An independent two-stage DCF analysis by a frontier AI model.
" data-astro-cid-3fhc5hvc> A conservative estimate for CVS. Despite its massive scale and diverse operations (Aetna, Caremark, Pharmacy), healthcare margins are under pressure. A 4% growth rate assumes they successfully navigate Medicare Advantage headwinds while capitalizing on their integrated care model.
" data-astro-cid-3fhc5hvc> The required return. With the 10-Year Treasury at 4.18%, a 9% discount rate implies an equity risk premium suitable for a mature, heavily regulated, but stable healthcare conglomerate like CVS.
" data-astro-cid-3fhc5hvc> 2% represents steady-state growth roughly mirroring long-term U.m. economic growth and inflation. We do not assume CVS will outpace general economic growth in perpetuity.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $12.13 | $10.40 | $9.10 | $8.09 | $7.28 |
| 1.5% | $13.24 | $11.20 | $9.71 | $8.56 | $7.66 |
| 2.0% | $14.56 | $12.13 | $10.40 | $9.10 | $8.09 |
| 2.5% | $16.18 | $13.24 | $11.20 | $9.71 | $8.56 |
| 3.0% | $18.20 | $14.56 | $12.13 | $10.40 | $9.10 |
■ Undervalued vs current price ■ Overvalued vs current price
CVS Health is undergoing a massive and turbulent transformation from a retail pharmacy into a vertically integrated healthcare behemoth encompassing insurance (Aetna), PBM (Caremark), and primary care (Oak Street Health). While its sheer scale creates a significant economic moat, execution missteps in its Medicare Advantage business, rising medical costs, and intense scrutiny of the PBM model have severely pressured margins. The long-term thesis of capturing value across the entire patient lifecycle remains compelling, but near-term competitive momentum and sentiment are historically weak as management struggles to stabilize the ship.
CVS is currently facing severe headwinds. Mispricing in its Medicare Advantage book and intense pharmacy reimbursement pressures are crushing its momentum.
Despite immense operational struggles, CVS Health possesses a formidable moat derived from its unmatched scale and vertical integration across the healthcare spectrum.
Sentiment is overwhelmingly negative, reflecting deep skepticism regarding management execution, guidance cuts, and the structural challenges facing the Medicare Advantage market.
Westmount Research. "CVS Health (CVS) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 19, 2026.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.